Geo News
Community curated by people like you
LatestAICryptoHealthWorld AffairsUS Politics
←Back to story

Novo says Wegovy injection lowers BMI and obesity rates in children in trial

CNBCView source article

Part of story

Novo Nordisk's Wegovy shows weight-loss benefit in children as young as six

Novo Nordisk released full Phase 3 trial results showing Wegovy lowered BMI and obesity rates in children aged 6 and older, though younger children who took the drug showed reduced growth rates.

Nov 16, 2026·3 sourcesClinical trialsDrug Policy, Pricing & ApprovalObesity treatmentNovo NordiskDrug safetyAdolescent healthGLP-1 drugsZepboundChildhood obesityWeight loss drugsEli Lilly
Novo Nordisk's Wegovy shows weight-loss benefit in children as young as six
00

Other sources for this story

The Wall Street Journal

Weight-Loss Drugs for Elementary-Age Children Succeed in Study

Financial Times

Six-year-olds. Novo’s new frontier for weight-loss drugs